期刊
JOURNAL OF NEUROIMMUNOLOGY
卷 277, 期 1-2, 页码 193-196出版社
ELSEVIER SCIENCE BV
DOI: 10.1016/j.jneuroim.2014.10.009
关键词
Multiple sclerosis; Interferon beta; Lymphocytes; Dopaminergic receptors; beta(2)-Adrenoceptors; Tyrosine hydroxylase
Interferon (IFN)-beta is among the first-line therapies for multiple sclerosis (MS), however the clinical response varies among individuals, and early identification of responders and non-responders would be of critical importance. Here we show that before treatment circulating lymphocytes of MS patients who will respond to IFN-beta have higher mRNA levels for the D-1-like dopaminergic receptor (DR) D-5 in comparison to cells from those who will not respond. Lymphocyte DR D-5 is reduced in MS and IFN-beta restores their expression and responsiveness. DR D-5 mRNA levels in circulating lymphocytes might represent an early marker of response to IFN-beta in MS patients. (C) 2014 Elsevier B.V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据